

# Tarah J Ballinger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5648779/publications.pdf>

Version: 2024-02-01

25  
papers

974  
citations

840776

11  
h-index

677142

22  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1859  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Subtyping of triple-negative breast cancer: Implications for therapy. <i>Cancer</i> , 2015, 121, 8-16.  | 4.1 | 280       |
| 2  | TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.  | 1.6 | 276       |
| 3  | Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1410.                             | 7.1 | 161       |
| 4  | Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 308.   | 2.8 | 62        |
| 5  | Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy. <i>Clinical Breast Cancer</i> , 2015, 15, 171-180.  | 2.4 | 35        |
| 6  | BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 345-355. | 1.6 | 23        |
| 7  | Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 389-399.  | 2.5 | 20        |
| 8  | Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 3520-3528.                   | 7.0 | 19        |
| 9  | Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC. <i>Clinical Cancer Research</i> , 2021, 27, 5810-5817.   | 7.0 | 19        |
| 10 | Impact of primary breast cancer therapy on energetic capacity and body composition. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 445-452.   | 2.5 | 16        |
| 11 | How we manage <sc>JAK</sc> inhibition in allogeneic transplantation for myelofibrosis. <i>European Journal of Haematology</i> , 2015, 94, 115-119.  | 2.2 | 14        |
| 12 | Discerning the clinical relevance of biomarkers in early stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 89-97.   | 2.5 | 9         |
| 13 | A Personalized, Dynamic Physical Activity Intervention Is Feasible and Improves Energetic Capacity, Energy Expenditure, and Quality of Life in Breast Cancer Survivors. <i>Frontiers in Oncology</i> , 2021, 11, 626180.                  | 2.8 | 7         |
| 14 | Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3235-3241.   | 7.0 | 6         |
| 15 | Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158. <i>Clinical Cancer Research</i> , 2021, 27, 1195-1199.                   | 7.0 | 5         |
| 16 | Impact of African ancestry on the relationship between body mass index and survival in an early-stage breast cancer trial (ECOG-ACRIN E5103). <i>Cancer</i> , 2022, 128, 2174-2181.   | 4.1 | 5         |
| 17 | Patient-reported outcomes in the Translational Breast Cancer Research Consortium. <i>Cancer</i> , 2020, 126, 922-930.   | 4.1 | 4         |
| 18 | Landmark trials in the medical oncology management of metastatic breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 246-258.  | 2.2 | 4         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Evaluation of an Extended-duration Chemoprophylaxis Regimen for Venous Thromboembolism after Microsurgical Breast Reconstruction. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2021, 9, e3741.                                      | 0.6 | 4         |
| 20 | Triple Negative Breast Cancer—Review of Current and Emerging Therapeutic Strategies. <i>Oncology &amp; Hematology Review</i> , 2016, 12, 89.   | 0.2 | 3         |
| 21 | Protocol of a randomized trial of acceptance and commitment therapy for fatigue interference in metastatic breast cancer. <i>Contemporary Clinical Trials</i> , 2020, 98, 106168.  | 1.8 | 1         |
| 22 | Impact of Genetic Ancestry on Treatment Toxicity and Racial Disparities in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2020, 12, 161-167.  | 1.0 | 1         |
| 23 | Cancer-Associated Muscle Dysfunction. , 2020, , 379-389.   |     | 0         |
| 24 | Abstract PD9-10: BRE12-158: A post-neoadjuvant, randomized phase 2 trial of personalized therapy vs. treatment of physician’s choice for patients with residual triple negative breast cancer. <i>Cancer Research</i> , 2022, 82, PD9-10-PD9-10. | 0.9 | 0         |
| 25 | Reply to K. Nozawa et al. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200288.  | 1.6 | 0         |